Corticosteroids for preventing postherpetic neuralgia

疱疹后神经痛 医学 安慰剂 梅德林 神经痛 相对风险 随机对照试验 置信区间 木瓦 临床试验 荟萃分析 麻醉 内科学 替代医学 神经病理性疼痛 病毒 免疫学 病理 法学 政治学
作者
Xin Jiang,Yanbo Li,Ning Chen,Muke Zhou,Li He
出处
期刊:The Cochrane library [Elsevier BV]
卷期号:2023 (12) 被引量:2
标识
DOI:10.1002/14651858.cd005582.pub5
摘要

Background Postherpetic neuralgia (PHN) is a common, serious, painful complication of herpes zoster. Corticosteroids have anti‐inflammatory properties, and might be beneficial. This is an update of a review first published in 2008, and previously updated in 2013. Objectives To assess the effects (benefits and harms) of corticosteroids in preventing postherpetic neuralgia. Search methods We updated the searches for randomised controlled trials (RCTs) of corticosteroids for preventing postherpetic neuralgia in the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, two other databases, and two trials registers (June 2022). We also reviewed the bibliographies of identified trials, contacted authors, and approached pharmaceutical companies to identify additional published or unpublished data. Selection criteria We included all RCTs involving corticosteroids given by oral, intramuscular, or intravenous routes for people of all ages, with herpes zoster of all degrees of severity within seven days after onset, compared with no treatment or placebo, but not with other treatments. Data collection and analysis Two review authors independently identified potential articles, extracted data, assessed the risk of bias of each trial, and the certainty of the evidence. Disagreement was resolved by discussion among the co‐authors. We followed standard Cochrane methodology. Main results We identified five trials with a total of 787 participants that met our inclusion criteria. No new studies were identified for this update. All were randomised, double‐blind, placebo‐controlled parallel‐group studies. The evidence is very uncertain about the effects of corticosteroids given orally during an acute herpes zoster infection in preventing postherpetic neuralgia six months after the onset of herpes (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.45 to 1.99; 2 trials, 114 participants; very low‐certainty evidence (downgraded for serious risk of bias and very serious imprecision)). The three other trials that fulfilled our inclusion criteria were not included in the meta‐analysis because they did not provide separate information on the number of participants with PHN at six months. Adverse events during or within two weeks after stopping treatment were reported in all five included trials. There were no observed differences in serious (RR 1.65, 95% CI 0.51 to 5.29; 5 trials, 755 participants; very low‐certainty evidence (downgraded for serious risk of bias and very serious imprecision)), or non‐serious adverse events (RR 1.30, 95% CI 0.90 to 1.87; 5 trials, 755 participants; low‐certainty evidence (downgraded for serious risk of bias and serious imprecision)) between the corticosteroid and placebo groups. One of these trials was at high risk of bias because of incomplete outcome data, two were at unclear risk of bias, and the other was at low risk of bias. The review was first published in 2008; no new RCTs were identified for inclusion in subsequent updates in 2010, 2013, and 2023. Authors' conclusions Based on the current available evidence, we are uncertain about the effects of corticosteroids given orally during an acute herpes zoster infection on preventing postherpetic neuralgia. Corticosteroids given orally or intramuscularly may result in little to no difference in the risk of adverse events in people with acute herpes zoster. Some researchers have recommended using corticosteroids to relieve the zoster‐associated pain in the acute phase of the disease. If further research is designed to evaluate the efficacy of corticosteroids for herpes zoster, long‐term follow‐up should be included to observe their effect on the transition from acute pain to postherpetic neuralgia. Future trials should include measurements of function and quality of life, as well as updated measures of pain.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
简单生活完成签到 ,获得积分10
刚刚
细腻驳发布了新的文献求助10
刚刚
小休完成签到 ,获得积分10
1秒前
呋喃完成签到,获得积分10
1秒前
017完成签到 ,获得积分20
1秒前
北23333完成签到,获得积分10
2秒前
精明向真完成签到,获得积分10
2秒前
WNL完成签到,获得积分10
2秒前
2秒前
时迁完成签到 ,获得积分10
3秒前
明理的蜗牛完成签到,获得积分10
3秒前
明天更好发布了新的文献求助10
3秒前
曾恒敬完成签到,获得积分10
3秒前
Overlord完成签到,获得积分10
3秒前
沉默的莞完成签到,获得积分10
4秒前
xucc完成签到,获得积分10
4秒前
江湖人称TonyJ完成签到,获得积分10
4秒前
Sumlower完成签到,获得积分10
4秒前
愉快续完成签到 ,获得积分10
5秒前
恣意完成签到 ,获得积分10
5秒前
6秒前
反方向的钟完成签到,获得积分10
6秒前
Junt完成签到,获得积分10
6秒前
石守鹏完成签到,获得积分10
6秒前
嘎嘣脆发布了新的文献求助10
7秒前
QQ小杰完成签到,获得积分10
7秒前
12完成签到 ,获得积分10
7秒前
mickiller完成签到,获得积分10
7秒前
香蕉觅云的应助被biotech_soldier采纳,获得20
7秒前
汶溢完成签到,获得积分10
7秒前
huangyi完成签到 ,获得积分10
7秒前
小二郎的应助被晨曦采纳,获得10
7秒前
李多意完成签到,获得积分10
8秒前
8秒前
李健的应助被aaa采纳,获得10
9秒前
小光完成签到,获得积分10
9秒前
悦耳的口红完成签到,获得积分10
9秒前
qducly2026完成签到,获得积分10
9秒前
西边的海完成签到,获得积分10
9秒前
花花花完成签到 ,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464